Skip to Main Content

Paper Details

Poziotinib in Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial.
J Clin Oncol
74
2022
ERBB2, Erb-b2 receptor tyrosine kinase 2 gene, HER2, HER2 Exon 20 Insertion Mutations, HER2 exon 20 insertions, HER2 mutations, NSCLC, NSCLCs, Non-Small-Cell Lung Cancer, Poziotinib, advanced or metastatic NSCLC, central nervous system, diarrhea, exon 20, patients, poziotinib, rash, stomatitis, tumor, tyrosine, tyrosine kinase
Author NameAffiliation
Jonathan W GoldmanDavid Geffen School of Medicine at university of california los angeles
Jonathan W GoldmanDavid Geffen School of Medicine at university of california los angeles
  • 1 - 2

Datasets

Release 1.2